Literature DB >> 3829053

Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study.

L Pedersen, C Rose, E Langvad.   

Abstract

Immunostimulant therapy with coumarin and cimetidine was evaluated in 17 patients with advanced malignant melanoma. Induction therapy with coumarin 100 mg daily was given for 8 weeks, whereupon cimetidine 1000 mg daily was added. No patients had been previously treated with cytotoxic drugs, and all patients had a good performance status. In 16 patients progressive disease was observed, and only 1 patient experienced no change in condition, lasting 30 weeks. We conclude that treatment with this schedule of coumarin and cimetidine is without effect in advanced malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829053     DOI: 10.1007/bf00205597

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

1.  Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive phase II trials.

Authors:  C Rose; L Pedersen; H T Mouridsen
Journal:  Eur J Cancer Clin Oncol       Date:  1985-10

2.  Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.

Authors:  P Flodgren; S Borgström; P E Jönsson; C Lindström; H O Sjögren
Journal:  Int J Cancer       Date:  1983-12-15       Impact factor: 7.396

  2 in total
  3 in total

1.  Synergistic effect of coumarin (1,2 benzopyrone) and endotoxin in the induction of human interleukin-1.

Authors:  K Stuhlmeier; G Theyer; G Baumgartner; G J Zlabinger
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

2.  Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study.

Authors:  M E Marshall; K Butler; J Cantrell; C Wiseman; L Mendelsohn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.

Authors:  J L Mohler; B T Williams; I M Thompson; M E Marshall
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.